Picture of Vaxart logo

VXRT — Vaxart News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapTurnaround

Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview

* Vaxart Inc  VXRT.OQ   VXRT.O  is expected to show a fall
in
quarterly revenue when it reports  results on November 13 for
the period ending January 1 0001
    * The South San Francisco California-based  company is
expected to
report a 59.5% decrease in revenue to $850 thousand from $2.1
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vaxart Inc is for a loss
of 10
cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vaxart Inc
is
$4.00​, above​ its last closing price of $0.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  0.01        -0.03      -0.09     Missed  -237.5
 Mar. 31 2024  -0.14       -0.14      -0.14     Met     0
 Dec. 31 2023  -0.16       -0.14      -0.12     Beat    17.2​
 Jan. 1 0001   -0.18       -0.18      -0.11     Beat    37.7
 ​​Jun.        -0.18       -0.18      -0.16     Beat    11.1
 30 2023                                                
 Mar. 31 2023  -0.18       -0.19      -0.19     Met     -1.8​
 Jan. 1 0001   -0.22       -0.23      -0.18     Beat    20.9
 Sep. 30 2022  -0.25       -0.24      -0.23     Beat    5.2
 This summary was machine generated November 8 at 16:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Vaxart

See all news